Key result
Ubiquinol and d-ribose contribute to myocardial ATP generation and are being studied as supplemental treatments for patients with heart failure with preserved ejection fraction.
Why the study?
HFpEF is associated with reduced myocardial ATP production, leading to the study of ubiquinol and d-ribose as supplemental treatments to contribute to ATP generation.
Do ubiquinol and d-ribose improve outcomes in patients with HFpEF?
Do ubiquinol and d-ribose improve outcomes in patients with HFpEF?
Answers are grounded in this paper and cite their sources.
Ubiquinol and d-ribose are being investigated as potential supplemental treatments for HFpEF due to their role in myocardial ATP generation.
•Manuscript Highlights.•HFpEF is associated with reduced ATP production in the myocardium.•Ubiquinol and d-ribose both contribute to the generation of myocardial ATP.•Both ubiquinol and d-ribose are being studied as supplemental treatments for patients with HFpEF.
No takes yet. Share an insight, caveat, or question.
Pierce et al. (2020) studied this question. Ubiquinol and d-ribose contribute to myocardial ATP generation and are being studied as supplemental treatments for patients with heart failure with preserved ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: